---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-049669"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:41:18.815412+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Ocugen releases presentation with clinical data showing treatment benefit in retinal disease studies

## Summary
- Presentation shows mean change in total atrophy area from baseline reduced by 84% in treated group (0.12 mm²) vs untreated (0.73 mm²).
- Visual acuity improvement in treated eyes across multiple cohorts (006-001, 007-001, 006-004) compared to untreated.
- Treated mutant group shows better outcomes than untreated mutant in LL VA change over 6 months.
- Presentation posted on company website December 3, 2024 and may be used in investor discussions.

## SEC filing metadata
- accession: 0001628280-24-049669
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828024049669/0001628280-24-049669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828024049669/ocgn-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-049669
- JSON: https://secwatch.observer/filing/0001628280-24-049669.json
- Plain text: https://secwatch.observer/filing/0001628280-24-049669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.